Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference

ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application